Loading clinical trials...
Loading clinical trials...
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up
Conditions
Interventions
SPRX002
ARC-T Cells
Locations
5
United States
City of Hope
Duarte, California, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Montefiore Einstein Cancer Center
New Rochelle, New York, United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
November 28, 2022
Primary Completion Date
September 30, 2025
Completion Date
November 17, 2025
Last Updated
June 12, 2024
NCT05564390
NCT06847867
NCT07320235
NCT06782542
NCT07523555
NCT07295951
Lead Sponsor
Arcellx, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions